Sign in
Taking people in DenmarkPhase 2/3

Melatonin or low-dose quetiapine for sleep problems in teenagers with psychiatric disorders

Compares melatonin, low-dose quetiapine and placebo for insomnia in adolescents with psychiatric disorders.

Key facts

Who runs it
Region Hovedstaden
Where
Copenhagen Nv, DenmarkSee the site
Registry title
Melatonin versus quetiapine in adolescents (MEL-QUE-A)
Status
Recruiting
Phase
Phase 2/3
People taking part
255 people, planned
Started
18 Aug 2025
Expected to end
28 Feb 2029
Type of study
Interventional
Record updated
11 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adolescents aged 16 to 17 with a mental or behavioral disorder who also have insomnia (trouble sleeping). It compares melatonin, low-dose quetiapine and placebo (a dummy pill).

Age
16 to 17 years
Sex
All sexes can join
Disease stage
A current or previous mental or behavioral disorder (ICD-10 F20-F69, F84, F90-F95). Sleep problems at least three times per week in the past 3 months. Insomnia Severity Index score ≥11.
Earlier treatment
Non-drug options such as sleep hygiene education, a weighted blanket or other gravity products must have been tried without enough effect. People with F84 or F90 diagnoses must have had melatonin treatment before. People currently taking melatonin or quetiapine cannot join.

Main reasons for not taking part

  • Current treatment with melatonin or quetiapine
  • Severe other physical illness
  • BMI ≥ 35 kg/m2
  • Breastfeeding, or alcohol or drug dependency in the last 3 months
  • Higher heart risk, including a prolonged QT-interval on the ECG (heart tracing)

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • 16 to 17 years of age
  • ICD-10 diagnosis of a current or previous mental or behavioral disorder (F20-F69, F84, F90-F95)
  • For the diagnoses F84 and F90 a previous period of treatment with melatonin is required
  • Self-reported sleep difficulties at least three times per week in the preceding 3 months
  • Insomnia Severity Index score ≥11
  • Non-pharmacological treatment options including sleep hygiene education, weighted blanket or other gravity products have been tested with insufficient effect
  • Women of childbearing potential: negative pregnancy test at baseline and use of highly effective contraception measures
  • Informed consent provided by both the minor and the legally designated representative

Who cannot take part

  • Current treatment with melatonin or quetiapine
  • Increased cardiac risk as assessed by presence of cardiac risk factors, cardiac symptoms, or prolonged QT-interval at baseline electrocardiogram (ECG)
  • Severe somatic comorbidity
  • BMI ≥ 35 kg/m2
  • Breastfeeding
  • Alcohol and/or substance dependency (F1X.2) within the last 3 months
  • Inadequate Danish language skills
  • Not able to make an informed consent

Where in Denmark

  • Psykiatrisk Center KobenhavnCopenhagen Nv, DenmarkTaking people

About the trial

What the trial wants to find out

To examine the efficacy of melatonin or low-dose quetiapine versus placebo for treatment of insomnia.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Efficacy of melatonin, low-dose quetiapine, or placebo in adolescents with psychiatric disorders and comorbid insomnia: a randomized clinical trial
Plain-language title
Melatonin or low-dose quetiapine for sleep problems in teenagers with psychiatric disordersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
11 November 2026